Loading...
Researchers tested onabotulinum toxin-A (BoNT-A) masseter and temporalis injections for sleep-associated bruxism in a manufacturer-funded trial. After polysomnography to confirm bruxism, participants were randomized to injection of 200 units of BoNT-A (60 into each masseter and 40 into each temporalis) or to placebo injections. The primary efficacy endpoint was the clinical global impression (CGI), and the secondary outcome was a change on a visual analog scale (VAS) for bruxism and for pain, at 4 to 8 weeks after the injections.
Of 23 participants, 13 in the BoNT-A group and 9 in the placebo group completed the trial. CGI improved significantly more in the BoNT group, and the VAS similarly favored the BoNT-A group. Among exploratory outcome…